Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3090416 | 0.74 | ABCB1 (0.48) | KDM4EHRH3ABCB1SLC6A4DRD2 | |
| SCHEMBL23914453 | 0.71 | HRH3 (0.42) | KDM4EHRH3SLC6A4DRD2LMNA | |
| SCHEMBL23914273 | 0.71 | CHRNA7 (0.42) | KDM4EHRH3SLC6A4DRD2 | |
| SCHEMBL23913990 | 0.70 | HRH3 (0.41) | KDM4EHRH3SLC6A4DRD2SLC6A2 | |
| SCHEMBL10053031 | 0.68 | SLC6A4 (0.42) | KDM4ESLC6A4DRD2SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL7260146 | 0.68 | DRD2 (0.68) | HRH3SLC6A4DRD2 | |
| SCHEMBL5329930 | 0.66 | KDM4E (0.53) | KDM4ESLC6A4DRD2LMNASLC6A2 | |
| SCHEMBL9809156 | 0.66 | SLC6A4 (0.47) | KDM4ESLC6A4DRD2SLC6A2SLC6A3 | |
| SCHEMBL31010303 | 0.65 | KMT2A (0.74) | HRH3 | |
| SCHEMBL5195380 | 0.65 | KMT2A (0.74) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629268-B2 | Cyclisation process of forming a multiple ring compound | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-01-14 | — | — | US | disclosed |
| US-20130046090-A1 | CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2013-02-21 | — | — | US | disclosed |
| WO-2007097719-A1 | CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130046090-A1 | CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND | COASY, AKR1C4, AKR1C2 | KDM4E 3322/4885HRH3 4626/4885ABCB1 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.